Immunotherapy avelumab shows potential in rare gynaecologic cancer resistant to chemotherapy

"Given the number of patients with disease that did not relapse, and reduced toxicity compared with standard single-agent chemotherapy, avelumab merits additional investigation,” said ASCO President Howard Burris.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in